Source: Covexit

Professor Harvey Risch responded today to a post by Sebastian Rushworth M.D., a physician in Stockholm, Sweden, who maintains a popular blog on C19.

The post titled “Hydroxychloroquine for covid: Lifesaving or useless?” presents an analysis concluding that:

“the evidence that exists at the present point in time does not support the use of hydroxychloroquine as a treatment for covid.“

Even the use of the drug is dismissed for early treatment, in combination with other agents such as Zinc or Azithromycin, as Dr Rushworth states:

“There is a signal that hydroxychloroquine could potentially decrease the risk of serious illness when given within three days of symptom onset, but there still isn’t enough trial data available to know whether that signal is real or not.”

In his post, Dr Rushworth dismisses the peer reviewed study by Derwand, Scholz and Zelenko, about the outpatient practice of Dr Zelenko during the beginning of the pandemic in NY State, showing a considerable reduction in hospitalization thanks to outpatient treatment, and which we covered in detail in this webinar.

The Zelenko Early Treatment Study, the Role of Zinc, the Therapeutic Approach to COVID-19 in Germany

The full posting by Dr Rushworth, whom we previously interviewed about the C19 situation in Sweden, can be found here.>>  Interview with Adam Gaertner, Part 2

Below is Professor Risch’s response, initially posted on a discussion forum, and reproduced with permission. It is presented here not to stir controversy but to illustrate how the dismissal of observational studies still continues, with as consequence the rejection of the effectiveness of hydroxychloroquine, including for outpatient use.

You may remember our landmark interview with Professor Risch from last October.

Professor Harvey Risch Interview – Part 1

Remember also we stressed recently how observational studies are dismissed by Stanford Professor Ioannidis, on the occasion of a recent videoconference he gave to Professor Didier Raoult and colleagues at the IHU-Marseille, where some 11,000 outpatients have received hydroxychloroquine-based treatment, with very low mortality.

Ioannidis / Raoult: Dialogue of the Deaf?

Here is the response by Professor Risch:

“Sebastian, you do not understand epidemiology and have no professional expertise in epidemiology. You are not qualified to assert that “observational studies are rife with confounders” and dismiss a whole literature (if not a whole discipline) as supposedly flawed. You appear to know nothing about the body of work comparing randomized vs nonrandomized studies of the same associations.

This massive body of evidence, summarized by the Cochrane Library, demonstrates that well-conducted observational studies on average, produce very similar associations as the corresponding RCTs.

Treating RCTs as gold-standard evidence is naive and blind to the multitude of easy, hidden ways that RCTs can be and have been sabotaged to produce null or even opposite results.”

“As a clinician, you should know that Covid-19 outpatient disease is viral replication, vs hospitalized disease which is florid pneumonia. These are absolutely different conditions and studies of the treatment of one cannot be extrapolated to the treatment of the other.

Furthermore, studies of prevention (before infection) must also be kept separate from treatment, and so-called PEP post-exposure prevention studies are largely bogus altogether, because of the delays in patient recruitment, randomization, medication shipping and, most importantly, how long it takes to obtain adequate tissue levels to combat viral replication.

Empirical data of the last-mentioned are available from 5 trials in India, and show that it takes a cumulative oral dose of 2-2.4 gm which none of the PEP studies delivered in less than 3-4 additional days, making them studies of early treatment, not prevention, but with almost no salient endpoints.”

“You, like most academic physicians, appear never to have treated any Covid-19 outpatients. You are out of touch with the fact that dozens of clinicians in the US have now cumulatively saved the lives of at least 10,000 high-risk patients. You can poo poo all you like. Docs on the front lines know better than you, they see it everyday.

Harvey A. Risch, MD, PhD
Professor of Epidemiology
Yale School of Public Health

Brazil: ‘To say that hydroxychloroquine and ivermectin kill is a fallacy’, says president of the Federal Council of Medicine

Association of Italian Doctors successfully treats COVID patients with vitamin D and hydroxychloroquine

Association of Italian Doctors successfully treats COVID patients with vitamin D and hydroxychloroquine

This doctor cured 5000 corona patients with hydroxychloroquine

Timing and dosing are the key to HCQ + AZ treatment in elderly Covid-19 patients

The home care protocol for Covid has been updated to include hydroxychloroquine: Piedmont, Italy

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Dr. Harvey Risch: Hydroxychloroquine, Ivermectin, and Other Therapeutics Highly Effective in Early COVID Treatment

I’ve railed against this in the media that we are a part of, and the way that the propaganda reacts to this is, “Ignore it. Ignore all of this.” I’m saying this now because the general public has to be the one that gets angry. The general public should be furious at the way people have been treated in the country by suppression of these drugs, by that kind of website that suppresses the ability of doctors to practice medicine.

Read More »

A Judge Stands up to a Hospital: “Step Aside” and Give a Dying Man Ivermectin

The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”

Read More »